Thrombosis
Conditions
Keywords
neonates, thrombosis, bivalirudin, direct thrombin inhibitor
Brief summary
The goals of this study are: 1. To assess the safety of bivalirudin in infants under six months with arterial or venous thrombosis; 2. To determine the dose of bivalirudin required to achieve adequate anticoagulation as measured by the activated clotting time (ACT) or activated partial thromboplastin time (aPTT) in Infants Under Six Months with arterial or venous thrombosis; 3. To determine the outcome of patients on bivalirudin with respect to thrombus resolution and bleeding complications compared to patients on unfractionated heparin (UH) or low molecular weight heparin (LMWH).
Detailed description
The goals of this study are: 1. To assess the safety of bivalirudin in infants under six months with arterial or venous thrombosis; 2. To determine the dose of bivalirudin required to achieve adequate anticoagulation as measured by the activated clotting time (ACT) or activated partial thromboplastin time (aPTT) in Infants Under Six Months with arterial or venous thrombosis; 3. To determine the outcome of patients on bivalirudin with respect to thrombus resolution and bleeding complications compared to patients on unfractionated heparin (UH) or low molecular weight heparin (LMWH).
Interventions
Sponsors
The Medicines Company
Study design
Allocation
NON_RANDOMIZED
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
0 Years to 6 Months
Healthy volunteers
No
Inclusion criteria
* Parent/legal-guardian has provided written informed consent before initiation of any study related procedures. * Objectively confirmed thrombotic event by either doppler ultrasound, echocardiogram, CT scan, MRI, MR angiogram, MR venogram, venogram or arteriogram. * Age less than 6 months . * Gestational age greater than 35 weeks * Expected life expectancy at least 14 days. * No contraindication to anticoagulation i.e. bleeding complications.
Exclusion criteria
* Active or recent (less than 7 days) bleeding. * Known allergy to Angiomax or hirudin, or known sensitivity to any component of the product. * Participation in other clinical research studies involving the evaluation of other investigational drugs or devices within 30 days of enrollment. * Refusal to undergo blood transfusion should it become necessary. * Any other disease or condition, which, in the judgment of the Investigator would place a patient at undue risk by being enrolled in the trial. * Baseline prolonged PT (\>18 secs) or aPTT (\>55 secs) * Platelet count \< 50,000 cells/mm3 * Birth Trauma * Planned or indicated surgery within 30 days * Major or minor bleeding event
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Observation of improvement for thrombosis or by clinical exam such as: Decrease in size of thrombus, restoration of flow through an occluded vessel, decrease in diameter of extremity or head. | — |
Secondary
| Measure | Time frame |
|---|---|
| In addition, efficacy will also be judged by demonstrating a decrease in the molecular markers of thrombin generation. | — |
Countries
United States
Outcome results
None listed